BTCY · Biotricity Inc.
$0.66
At close · Aug 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 19, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Those conditions raise substantial doubt about its ability to continue as a going concern for a period of one year from the issuance of these condensed consolidated interim financial statements.”View the 10-Q filed Aug 19, 2026
Market Cap
$2.59M
Shares
19.91M
Volume · Aug 5
321.5K
Avg daily vol (3M)
78.21K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.66
Open$0.42
Day$0.38–0.71
52W close$0.46–2.50
Avg vol 30d101K
Short int124K · 0.6% float · 5.1d
Short vol0%
Last earningsFeb 18, 2026
DataJan 2020–Aug 2024
Filing10-Q · Aug 19
Up next
filed Aug 19, 2026
call held Nov 18, 2025
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-73.9%
Trailing year
Short interest
—
Latest settlement
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−39%
below
Price vs 50-day avg
−26%
below
RSI (14)
42
neutral
MACD trend
Negative
52-week position
10%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−14%
trailing
6-month return
−18%
trailing
YTD return
−43%
this year
Relative strength
−21%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-50% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.62% of float · ▲ +6.0% MoM · 5.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1 holders — near 4-yr low, contrarian setup
Fundamentals
Gross margin
3252%
EPS growth
+79%
Y/Y
Free cash flow
$-748.7K
Quant / Vol
risk profile
Volatility
115%
annualized · 1-yr
Max drawdown
−82%
past year
ATR
16.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Dec 31, 2020
Quarter-over-quarter growth
· the next few quarters
25% – 40%
Guided vs delivered
· last 1 settled
Revenue
fiscal year ending March 31, 2022
guided $8M – $10M
$7.65M
Miss −15.0%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−39%
Bearish
Price vs 50-day avg
−26%
Bearish
RSI (14)
42
Neutral
MACD trend
Negative
Bearish
52-week position
10%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-50% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.62% of float · ▲ +6.0% MoM · 5.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1 holders — near 4-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0
Now $1 · 10%
Range high $3
vs 200-day avg -39%
vs 50-day avg -26%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Gross Margin | 82.6% | Three months ended June 30, 2026 filing | — |
| Gross margin on technology fees | 86.9% | Three months ended June 30, 2026 filing | — |
| Operating margin | 3.7% | Three months ended June 30, 2026 filing | — |
| Recurring technology fee revenue growth | 23.6% | Three months ended June 30, 2026 filing | — |
| Technology fees as percentage of total revenue | 97.4% | Three months ended June 30, 2026 filing | — |
| Adjusted EBITDA non-GAAP | $1,722,821 | Year ended March 31, 2026 filing | — |
| EBITDA non-GAAP | $1,709,660 | Year ended March 31, 2026 filing | — |
| Research and development costs | $2.7M | fiscal year ended March 31, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BTCY
this stock
Biotricity Inc.
|
$2.59M | — | +16.0% | — | 0.6% |
|
ABT
Abbott Laboratories
|
$174.90B | -20.1% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -8.4% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -18.8% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -55.5% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
1
- % held
- 0.2%
- Net QoQ
- -18.3K sh
- Top holder
- Strengthening Families &…
Held
Float
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BTCY | -5.7% | -14.3% | -17.5% | -4.4% | -42.6% |
| SPY | -5.0% | -6.8% | +3.3% | -6.1% | +8.9% |
| vs SPY | -0.7% | -7.5% | -20.8% | +1.6% | -51.5% |